VanEck Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.2M | Buy |
53,879
+4,139
| +8% | +$723K | 0.01% | 597 |
|
|
2025
Q4 | $8.46M | Buy |
49,740
+25,445
| +105% | +$3.9M | 0.01% | 616 |
|
|
2025
Q3 | $3.2M | Sell |
24,295
-8,504
| -26% | -$1.02M | ﹤0.01% | 896 |
|
|
2025
Q2 | $3.48M | Sell |
32,799
-76,052
| -70% | -$8.26M | ﹤0.01% | 852 |
|
|
2025
Q1 | $13.5M | Buy |
108,851
+59,472
| +120% | +$7.76M | 0.02% | 395 |
|
|
2024
Q4 | $6.08M | Sell |
49,379
-10,832
| -18% | -$1.28M | 0.01% | 613 |
|
|
2024
Q3 | $6.69M | Buy |
60,211
+6,157
| +11% | +$675K | 0.01% | 557 |
|
|
2024
Q2 | $5.77M | Buy |
54,054
+2,361
| +5% | +$260K | 0.01% | 539 |
|
|
2024
Q1 | $6.22M | Sell |
51,693
-26,315
| -34% | -$3.22M | 0.01% | 519 |
|
|
2023
Q4 | $9.6M | Sell |
78,008
-7,514
| -9% | -$938K | 0.02% | 380 |
|
|
2023
Q3 | $11.1M | Sell |
85,522
-27,138
| -24% | -$3.62M | 0.02% | 326 |
|
|
2023
Q2 | $14M | Buy |
112,660
+46,908
| +71% | +$6.31M | 0.03% | 298 |
|
|
2023
Q1 | $9.62M | Sell |
65,752
-45,271
| -41% | -$6.7M | 0.02% | 359 |
|
|
2022
Q4 | $17.7M | Buy |
111,023
+15,825
| +17% | +$2.32M | 0.05% | 256 |
|
|
2022
Q3 | $12.7M | Sell |
95,198
-42,293
| -31% | -$6.43M | 0.04% | 277 |
|
|
2022
Q2 | $21.4M | Buy |
137,491
+62,815
| +84% | +$9.67M | 0.06% | 238 |
|
|
2022
Q1 | $11.6M | Buy |
74,676
+1
| +0% | +$145 | 0.02% | 342 |
|
|
2021
Q4 | $9.51M | Buy |
74,675
+15,650
| +27% | +$2.06M | 0.02% | 384 |
|
|
2021
Q3 | $7.69M | Buy |
59,025
+19,836
| +51% | +$3M | 0.02% | 384 |
|
|
2021
Q2 | $6.96M | Buy |
39,189
+540
| +1% | +$93.5K | 0.02% | 400 |
|
|
2021
Q1 | $6.35M | Sell |
38,649
-20,768
| -35% | -$3.42M | 0.02% | 401 |
|
|
2020
Q4 | $9.81M | Sell |
59,417
-5,519
| -8% | -$822K | 0.03% | 314 |
|
|
2020
Q3 | $9.26M | Buy |
64,936
+7,446
| +13% | +$923K | 0.03% | 273 |
|
|
2020
Q2 | $6.34M | Buy |
57,490
+5,104
| +10% | +$564K | 0.02% | 312 |
|
|
2020
Q1 | $5.22M | Buy |
52,386
+8,611
| +20% | +$1.11M | 0.03% | 295 |
|
|
2019
Q4 | $6.54M | Buy |
43,775
+10,761
| +33% | +$1.46M | 0.03% | 326 |
|
|
2019
Q3 | $4.23M | Sell |
33,014
-18,847
| -36% | -$2.53M | 0.02% | 361 |
|
|
2019
Q2 | $7.39M | Sell |
51,861
-251
| -0.5% | -$33.7K | 0.04% | 272 |
|
|
2019
Q1 | $7.45M | Sell |
52,112
-27,559
| -35% | -$3.59M | 0.04% | 264 |
|
|
2018
Q4 | $9.88M | Buy |
79,671
+6,502
| +9% | +$965K | 0.05% | 227 |
|
|
2018
Q3 | $12.3M | Buy |
73,169
+1,474
| +2% | +$253K | 0.06% | 230 |
|
|
2018
Q2 | $12.4M | Sell |
71,695
-5,858
| -8% | -$958K | 0.06% | 218 |
|
|
2018
Q1 | $11.7M | Sell |
77,553
-9,366
| -11% | -$1.37M | 0.06% | 224 |
|
|
2017
Q4 | $11.7M | Buy |
86,919
+3,709
| +4% | +$514K | 0.06% | 222 |
|
|
2017
Q3 | $12.2M | Buy |
83,210
+32,360
| +64% | +$4.89M | 0.06% | 229 |
|
|
2017
Q2 | $7.91M | Sell |
50,850
-9,199
| -15% | -$1.41M | 0.04% | 240 |
|
|
2017
Q1 | $8.71M | Buy |
60,049
+34,276
| +133% | +$4.46M | 0.04% | 239 |
|
|
2016
Q4 | $2.81M | Sell |
25,773
-6,346
| -20% | -$707K | 0.01% | 361 |
|
|
2016
Q3 | $3.9M | Buy |
32,119
+4,230
| +15% | +$570K | 0.02% | 321 |
|
|
2016
Q2 | $3.94M | Buy |
27,889
+6,189
| +29% | +$912K | 0.02% | 301 |
|
|
2016
Q1 | $2.83M | Buy |
21,700
+945
| +5% | +$118K | 0.02% | 307 |
|
|
2015
Q4 | $2.92M | Buy |
20,755
+1,905
| +10% | +$264K | 0.02% | 275 |
|
|
2015
Q3 | $2.5M | Buy |
18,850
+2,677
| +17% | +$461K | 0.02% | 298 |
|
|
2015
Q2 | $2.85M | Buy |
+16,173
| New | +$2.9M | 0.02% | 330 |
|
Other funds holding JAZZ
VPM
VCM
EC
VanEck Associates's JAZZ Position: Q1 2026 in Review
VanEck Associates increased its Jazz Pharmaceuticals (JAZZ) stake by 8.3% in Q1 2026, buying an estimated $723K and bringing the position to 53,879 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #597.
VanEck Associates first reported a position in JAZZ in Q2 2015 and has held it in 44 quarters since. The position peaked at $21.4M in Q2 2022. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- VanEck Associates held 53,879 shares of Jazz Pharmaceuticals worth $10.2M as of Q1 2026.
- VanEck Associates bought 4,139 Jazz Pharmaceuticals shares in Q1 2026, an estimated $723K.
- Jazz Pharmaceuticals made up 0.01% of VanEck Associates's portfolio in Q1 2026, its #597 holding.
- VanEck Associates first reported a position in Jazz Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
- VanEck Associates's Jazz Pharmaceuticals position peaked at $21.4M in Q2 2022.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.